Evaluation of SARS-CoV2-specific serum parameters in blood samples of SARS-CoV2-seronegative healthy volunteers, hospitalized SARS-CoV2-patients with acute disease and recovered SARS-CoV2-patients with asymptomatic/mild/severe disease.

Evaluation of SARS-CoV2-specific serum parameters in blood samples of SARS-CoV2-seronegative healthy volunteers, hospitalized SARS-CoV2-patients with acute disease and recovered SARS-CoV2-patients with asymptomatic/mild/severe disease. - COVIAS - SARS-CoV-2-Induced Alterations in Serum Parameters

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

DRKS

Registry ID

DRKS00023877

Enrollment

150

Registered

2020-12-15

Start date

2021-04-15

Completion date

Unknown

Last updated

2025-04-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

U07.1

Interventions

Group 1: Single blood drawing

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Inclusion criteria

Inclusion criteria: 1. Signed informed consent. 2. At least one positive SARS-CoV-2 swab/PCR-test (groups b-e). 3. Availability of data (e.g. discharge letters) to assign the patient in one of the groups (asymptomatic/mild/severe) and to document the course of the COVID-19-disease. 4. Subject/patient is at least 18 years old and able to give informed consent.

Exclusion criteria

Exclusion criteria: 1. Every disease or status that does not allow the blood drawing according to the assessment of the consenting physician.

Design outcomes

Primary

Measure	Time frame
This trial does not fall under the German drug or device law as no drug is applied; only one blood drawing takes place. The aim of this trial is to compare SARS-CoV-2-specific serum parameters (e.g. IgG-, IgA-, IgM-level, lipids etc.) of different populations (SARS-CoV-2-seronegative subjects, patients with acute COVID-19 disease as well as of recovered SARS-CoV-2-patients with asymptomatic/mild/severe disease). This trial is designed to establish assays that can be used in the future to clinical trials with patients suffering from COVID-19. The results of this trial might also be used in drug development projects.	—

Measure

Time frame

This trial does not fall under the German drug or device law as no drug is applied; only one blood drawing takes place. The aim of this trial is to compare SARS-CoV-2-specific serum parameters (e.g. IgG-, IgA-, IgM-level, lipids etc.) of different populations (SARS-CoV-2-seronegative subjects, patients with acute COVID-19 disease as well as of recovered SARS-CoV-2-patients with asymptomatic/mild/severe disease). This trial is designed to establish assays that can be used in the future to clinical trials with patients suffering from COVID-19. The results of this trial might also be used in drug development projects.

—

Countries

Germany

Outcome results

None listed

Source: DRKS (via WHO ICTRP) · Data processed: Feb 4, 2026